Page 94 - Micron News Today

Fab toolmaker Marketech International expects to generate flat or slight revenue growth this year, judging from the NT$60 billion (US$1.97 billion) worth of orders it has on hand.

Samsung has announced that starting this week it will be lowering memory chips production by a meaningful level, especially that of products with supply secured, and most market observers believe that the production cut will focus on DDR4 memory chips.

Angered by Washingtons moves to limit Chinas access to technology to manufacture highly-advanced semiconductors, key Chinese leaders are still struggling to figure out how to apply various retaliatory measures without curbing their ambitions in the chip industry.

China has kicked off a cybersecurity review of Micron Technologys memory products sold in the country, making it the first foreign semiconductor company in China to face the scrutiny and casting darker clouds over its business prospects. It remains to be seen what the possible consequences will be, and if China will conduct similar probes into other foreign semiconductor firms.

Taiwan-based OSATs such as ChipMOS Technologies and Chipbond Technology are seeing the monthly operating growth rate of chip and backend companies exceed 20%.

The worlds most important chip maker reported a 15% year-over-year decline in March revenue.

Micron Technology, Inc. is currently at $63.45, up $4.89 or 8.35% --Would be highest close since March 29, 2023, when it closed at $63.54 --On pace for largest percent increase... | April 10, 2023

As Cayuga County seeks to capitalize on the Micron project planned for neighboring Onondaga County, it is preparing to meet the demand for energy if there is an influx of

A team led by researchers at Weill Cornell Medicine, the University of Wisconsin-Madison; Scripps Research and the University of Chicago has identified an antibody that appears to block infection by all dominant variants of the virus that causes COVID-19, including Omicron, the most recent.

Researchers assess the role of the live-attenuated vaccine sCPD9 in inducing systemic and mucosal immunity against SARS-CoV-2 variants.